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ABSTRACT 
 
THE INFLAMMASOME IN ACUTE MYOCARDITIS 
By Harsha Ramanujam Kannan, BS 
A thesis submitted in partial fulfillment of the requirements for the degree of Master 
of Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013. 
Sponsor: Antonio Abbate, MD, PhD, Department of Internal Medicine 
 
Acute myocarditis is an acute inflammatory syndrome characterized by myocardial 
damage and dysfunction often due to a viral infection followed by a variable development 
over time. There are currently no specific treatments and standard treatments for heart 
failure are generally applied. The inflammasome is a recently identified macromolecular 
structure that occupies a central role in the amplification of the inflammatory response and 
promotion of cell death during acute and chronic infections. We hypothesized the 
formation of the inflammasome in acute myocarditis. To investigate, samples of patients 
were collected from the Cardiomyopathy Registry in Trieste, with 12 cases of biopsy-
proven myocarditis and 11 cases of autopsy-proven myocarditis stained for major 
components of the inflammasome through immunofluorescence; 10 of the 12 (83.3%) 
biopsy cases and 8 of the 11 (72.7%) autopsy cases presented formation of the 
inflammasome in a variety of cells including resident cells (i.e. cardiomyocytes, endothelial 
cells, fibroblasts) and  infiltrating cells (i.e. leukocytes) while varying in intensity and 
distribution. Control samples of 5 subjects not presenting with any acute cardiac events 
showed no formation of the inflammasome. While further studies should look to elucidate 
the correlation of inflammasome-formation and progression of disease, this finding paves 
the way for further insight into the pathophysiology of acute myocarditis. 
  1 
INTRODUCTION 
 
ACUTE MYOCARDITIS 
 
Acute myocarditis is an inflammatory disorder of the heart muscle.1 Such definition 
covers a long list of clinical conditions in which the heart muscle (myocardium) is 
primarily involved in an acute inflammatory response that is not secondary to 
myocardial ischemia or toxic injury.1-3 Acute myocarditis refers both to the 
pathologic condition and the clinical manifestation (disease). 
 
The causes for this inflammatory response are many and vary from infectious 
(primarily viral, but also bacterial) to non-infectious (including ‘allergic’ and 
autoimmune).1-3 The variability in etiology is paralleled by a large variability in the 
clinical presentation, ranging from asymptomatic to cardiogenic shock and sudden 
death.1-3  
 
What is common to all these conditions is the presence of (a) myocardial injury + 
(b) an ensuing inflammatory response. The manifestation and severity of the 
disease is dependent on (a) and (b) and involves the intensity and nature of the 
injury and the response (Figure 1).1-4  
 
As such, acute myocarditis involves both cardiomyocyte dysfunction as a result of 
the initial virally mediated event as well as tissue injury due to subsequent immune 
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response. The immune-mediated response in reaction to the viral component 
leads to myocardial inflammation, necrotic events, and ventricular dysfunction. 
 
 
 
The exact incidence and prevalence of myocarditis is unknown.1-3 It is often under-
recognized or mis-diagnosed.1-3 This is consequential of the fact that many 
affected individuals may be asymptomatic at onset while others may be for the 
entire duration of the disease. It is estimated that 10% of patients with unexplained 
idiopathic cardiomyopathy, 50% with end-stage heart failure, and approximately 
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25% of all heart transplantations are due to myocarditis.5-7 Myocarditis is also 
found at autopsy in 5-20% of cases of sudden unexplained deaths in young 
adults.8-9 Finally, acute myocarditis mimics acute myocardial infarction and 
pericarditis, and while the literature is full of reports, the true incidence is unknown 
due to lack of systematic studies. 
 
The natural history of acute myocarditis also shows a wide-spectrum of clinical 
variability.1-4 Of patients with acute myocarditis, nearly 50% experience an 
improvement, whereas the rest will experience worsening cardiomyopathy and 
heart failure.1-4,11-12 The Myocarditis Treatment Trial published in 1995 included 
111 patients with biopsy-proven myocarditis and depressed left ventricular ejection 
fraction (LVEF, mean 25%).13 Patients had paired echocardiograms over 6 and 12  
months and were then followed for 5 years for survival. While there was a mean 
improvement in LVEF of approximately 10%, most patients continued to have 
depressed LVEF, and the 1-year and 5-year mortality rates were a remarkable 
20% and 56% respectively (Figure 2).13 A more recent prospective longitudinal 
study enrolling all-comers with biopsy-proven acute myocarditis published in 2012 
showed an approximate 5-year mortality of 20%, with patients with lower LVEF 
being more likely to die.14 These data show that despite improvements in the 
treatment of cardiomyopathy, patients with acute myocarditis are at greatly 
increased risk of death, especially if LV function is depressed. 
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Acute myocarditis is usually suspected on the basis of the clinical presentation but 
the diagnosis requires either confirmation with an endomyocardial biopsy (EMB) 
providing tissue for histologic assessment or with cardiac magnetic resonance 
which may show a characteristic pattern. Often the diagnosis is also supported by 
pertinent negative findings excluding other causes (i.e. ischemia). Pathological 
observation of acute myocarditis is defined by a leukocytic infiltrate associated 
with cardiomyocyte necrosis (in the absence of ischemia or toxic injury). 
Cardiotropic virus detection can be performed by PCR techniques and in situ 
hybridization to help identify cell types replicating viral genomes. 
 
At present day, there are no specific treatments for acute myocarditis, and thus 
standard treatments for heart failure are generally applied. The Myocarditis 
Treatment Trial randomized patients to immunosuppressive therapy with 
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prednisone with cyclosporine or azathioprine for 6 months but failed to show an 
improvement in LVEF or survival (Figure 2).13 A recent meta-analysis of clinical 
trials showed similar results on outcomes despite a small effect on LVEF.15 
Immunosuppressive treatment sees a more liberal use in Europe but is reserved to 
few specific cases in the USA.1-4 Antiviral treatment revolves around interferon-β 
and interferon (IFN)-α2 therapy, which in animal studies has shown to protect 
cardiomyocytes against injury and decrease inflammatory cell infiltrates. However, 
only IFN-β showed effective clearance of the viral load. Initial studies with 
treatment with IFN-β in selected patients with myocardial enteroviral or adenoviral 
persistence and LV dysfunction has shown to eliminate the viral genomes in those 
patients exhibiting these conditions and lead to improved LV function.3 
 
Specific risk stratification tools are also lacking in acute myocarditis. The 
commonly explored markers of immunopathology have failed to show a clear 
prediction in patients with biopsy-proven myocarditis.9 Similarly novel methods of 
detection have shown frequent presence of viral genome in biopsies16 but have 
failed to link a specific virus or the persistence of genome over time with 
prognosis.17-18 In some, but not all studies, lack of viral genome and presence of 
autoantibodies predicted response to treatment.19-20.  
 
The pathophysiologic mechanisms leading to successful healing and restitution ad 
integrum in some cases, or with impaired healing, fibrosis, and cardiomyopathy in 
others, are poorly understood.1-4,20-21. The initial injury often involves an infection 
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by a virus or intracellular bacterium. These cardiotrophic infectious pathogens 
determine an initial injury by replication within the cardiomyocytes. The cellular 
injury induces an inflammatory response characterized by an acute infiltrate of 
leukocytes to the heart primarily consisting of lymphocytes. Cytotoxic lymphocytes 
as well as cytotoxic antibodies are involved in the progression of the injury, 
whereas regulatory lymphocytes and neutralizing antibodies appear to be involved 
in protection 4,20-21. These factors, however, seem to poorly explain and poorly 
predict outcome and treatments directed specifically at lymphocytes (prednisone, 
cyclosporine, azathioprine) or autoantibodies (plasma derived immunoglobulins) 
have been disappointing.  
 
In conclusion, acute myocarditis is a rather common disease, with an unfavorable 
outcome, no specific therapies, poorly understood pathophysiologic mechanisms, 
and paucity of clinically useful predictors. It follows that there is an urgent need for 
further research in this area. In this study, we addressed the role of a new 
pathophysiologic mechanism with potential implications for diagnosis, 
prognostication, and therapy. 
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THE INFLAMMASOME 
 
The inflammasome is a recently identified macromolecular structure activated 
during cellular and tissue injury that amplifies the inflammatory response.22-23 
During infection or injury, pathogen-associated molecular patterns (PAMPs) or 
danger-associated molecular patterns (DAMPs) are sensed and lead to the 
triggering of the inflammasome. This step has been shown to represent an 
essential process in the initiation of the local and systemic inflammatory response 
in virtually all forms of infectious or sterile tissue injury. Viral infections are known 
to activate the inflammasome and the outcome of the infection is often determined 
by this interaction leading to either death of the infected cell (pyroptosis) and virus, 
or survival of both cell and virus.24 Hence, while viruses are inducers of the 
inflammasome per se, viral proteins may inhibit the inflammasome (“evasion”).24 It 
has been recently shown that during sterile ischemic injury to the heart the 
inflammasome promotes further damage.25 Others have shown that the same 
occurs in other cardiomyopathies.26-28 Yet there has been no report investigating 
the inflammasome in acute myocarditis. Understanding the pathophysiology of the 
inflammasome formation in the heart during acute myocarditis may provide clues 
into the clinical variability of acute myocarditis. 
 
The structure and function of the components of the inflammasome can be 
summarized with the presence of a sensor (that directly or indirectly binds PAMPs 
or DAMPs), an adaptor (scaffold), and an effector (enzyme).22-23 While there are 
several interchangeable sensors, caspase-1 is the common effector protein, and 
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defines the inflammasome. Caspase-1 (also called interleukin-1β converting 
enzyme) leads to the maturation of key pro-inflammatory cytokines such as 
interleukin-1β (IL-1β) and interleukin-18 (IL-18), and induces cell death by 
pyroptosis.29 The apoptosis-associated speck-like protein containing a caspase-1 
recruiting domain (ASC) is the most common adaptor serving as a scaffold for the 
inflammasome specks (visible at light microscopy)(Figures 3-4).22-23,30 Many of the 
effects of the inflammasome are mediated by the release of active IL-1β and IL-18.  
 
Recent pharmaceutical developments in this area have further stimulated the 
interest in the inflammasome, IL-1β, and IL-18 in many clinical conditions ranging 
from rare hereditary diseases related to mutations in inflammasome genes to more 
common illnesses like rheumatoid arthritis, gout, and diabetes.31-32 These 
disparate conditions have in common the property of being “auto-inflammatory”.33 
Great interest in the inflammasome is also evident in the infectious disease 
literature especially inherent to virus and bacteria.24,34 
 
We therefore hypothesize that the viral infection or the ensuing cellular destruction 
seen during acute myocarditis leads to the formation and activation of the 
inflammasome (Figure 3). Identifying a role of the inflammasome would provide an 
opportunity to explore inflammasome-related markers for diagnostic or prognostic 
purposes. Furthermore inhibitors of IL-1β and IL-18 are available and ready to be 
tested, while novel inhibitors are being developed. Recent clinical studies have 
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been completed, with 3 pilot clinical trials showing a favorable effect of anakinra 
(an IL-1 blocker) in patients with acute myocardial infarction or heart failure.35-37 
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APPROACH 
 
In this study, we investigated the presence of inflammasome in tissue samples 
obtained through autopsy or endomyocardial biopsy in patients with acute 
myocarditis. These experiments are made possible by the existence of a unique, 
well-designed and maintained Cardiomyopathy Registry held in Trieste, Italy, in 
which all patients with acute myocarditis are identified and followed prospectively, 
and in which heart specimens derived from endomyocardial biopsies or autopsies 
are stored for future studies.10,38-42 
 
The Cardiomyopathy Registry in Trieste was started on January 1, 1981 and it is 
still current. Between January 1981 and December 2012, the Registry included 98 
patients with biopsy-proven myocarditis (or autopsy-proven myocarditis if the 
patient deceased before the biopsy). All patients underwent clinical evaluation with 
laboratory testing, ECG, ECG Holter, echocardiography, coronary angiogram and 
endomyocardial biopsy (with classical pathology analyses). All patients received 
standard heart failure treatments according to guidelines, and were followed after 
6 and 12 months; those with heart failure symptoms or evidence of abnormal heart 
dimensions or function were followed every 6 months up to 48 months. 
Endomyocardial biopsies were obtained from the left and right ventricles. Samples 
were stored in formalin and then embedded in paraffin for histology and 
immunopathology, or snap frozen with liquid nitrogen for identification of viral 
genome. Mean age of the patients is 37, with 70% being males. The mortality 
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rates at 2 and 5 years were 11% and 17%, respectively. Approximately half of the 
patients presented with heart failure, and these were more likely to have 
depressed LVEF, with a much lower 5-year transplant-free survival (73%). 
 
We determined the presence of inflammasome aggregates in the different cell 
types (cardiomyocytes, leukocytes, fibroblasts, and endothelial cells). 
 
SELECTION OF THE CASES 
 
As explained earlier, acute myocarditis is a heterogeneous syndrome with wide 
variability in the modality of onset, severity of illness, cause and prognosis. In 
order to select a more homogeneous population for this study, we included 12 
cases of patients with acute myocarditis according to the Dallas criteria.43 We 
excluded patients with a longer duration of symptoms as well as asymptomatic 
patients, as this would limit our insight into the natural history of the disease. We 
excluded patients with eosinophilic myocarditis, giant-cell myocarditis, sarcoidosis, 
HIV cardiomyopathy, fungal, and protozoal myocarditis, since all these conditions 
are uniquely characterized by either a mechanism of disease, a specific and rather 
effective therapeutic strategy, or additional morbidities. This provided a rather 
homogenous cohort of cases with viral or autoimmune myocarditis of recent onset. 
Also included were 11 patients diagnosed at autopsy (fatal cases) for comparison.  
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SELECTION OF THE CONTROLS 
 
In order to evaluate the specificity of our findings, we included controls in which, 
according to our hypothesis, staining was not expected to present formation of the 
inflammasome. Five subjects were enrolled as controls and presented with chronic 
cardiac disease but without acute myocarditis or other acute cardiac event who 
died and underwent autopsy. 
 
PROCESSING OF THE SAMPLES 
 
The cases were identified in the registry, and the histological slides were prepared 
in Trieste, Italy, before being shipped to our laboratory at Virginia Commonwealth 
University. The slides were identified with a progressive number and not with the 
identity of the subject. The team in Trieste coded the samples in a way that the 
investigators in Virginia could not distinguish the identity of the cases. 
 
IDENTIFICATION OF THE INFLAMMASOME IN THE HEART 
 
We employed immunofluorescence staining using antibodies raised against ASC 
(Sigma Aldrich, PRS2287, rabbit polyclonal) and caspase-1 (Sigma Aldrich, 
C4851, rabbit polyclonal; Novus Biological, 14F468, mouse monoclonal). The 
rationale for using ASC or caspase-1 as main markers for the inflammasome is 
that although multiple sensors may be involved, the effector caspase-1 and 
adaptor protein ASC are by far the most common components of the 
inflammasome. Based on our hypothesis, we expected to see inflammasome 
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“specks” as peri-nuclear cytoplasmatic aggregates in the majority of heart samples 
with differing degrees of intensity and presence in different cell types including 
leukocytes, endothelial cells, fibroblasts and cardiomyocytes.  
 
To characterize the cellular pattern we used a double staining technique with 
antibodies against S100A4 (Sigma Aldrich, 7493P1, goat polyclonal) and CD31 
(Cell Signaling, #3528, mouse monoclonal) to recognize fibroblasts and 
endothelial cells respectively, plus cardiac actin (Sigma Aldrich, A9357, mouse 
monoclonal) as a marker to denote cardiomyocytes. 
 
STAINING OF THE SAMPLES 
 
Staining of samples occurred over three days, the first of which involved 
rehydration of samples, antigen retrieval, and application of primary antibody for 
ASC or caspase-1. Samples were taken through three changes of xylene, 5 
minutes each, two changes of 100% ethanol, and changes through 95% and 70% 
ethanol for a minute each before being placed in running tap water to remove 
paraffin embedding and rehydrate. Antigen retrieval was performed using a 
steamer with samples placed in 0.01M citrate buffer pH 6.0 for 20 minutes. 
Blocking to minimize non-specific binding used 1% normal donkey serum in PBS 
for 15 minutes. Application of primary antibody diluted 1:50 (ASC or caspase-1) in 
PBS was left to incubate overnight in 4°C.  
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Second day involved washing samples of the primary before application of 
fluorescence-conjugated secondary antibody diluted 1:100 in PBS incubated for 
four hours at room temperature. The second primary antibody, marking cell type, 
was diluted 1:100 in PBS, applied, and left to incubate overnight (4°C). The 
secondary antibody of a different fluorescence wavelength was applied and left to 
incubate for four hours on the third day (RT). 
 
Autofluorescence due to lipofuscin-like pigments is seen in the heart and central 
nervous system.45 The sarcomere may also be a source of autofluorescence.46 To 
account for this and ensure distinction of positive staining for only ASC and 
caspase-1, we used a solution of 1% Sudan Black in 70% Ethanol for five minutes 
following the application of the final secondary antibody, quenching the nonspecific 
fluorescence without compromising the signal of the specific antibodies.47 Nuclear 
staining was done with 4’,6-diamidino-2-phenylindole (DAPI) 1:1000 for 5 minutes 
and samples were cover slipped with a tris-glycerol mounting media.  
 
ASSESSMENT OF THE INFLAMMASOME IN THE HEART 
 
All the final images of samples were acquired with an IX70 microscope and 
cellSens Dimension digital imaging software (both Olympus) using a 40x objective 
(400x magnification). Filter sets from the software for each separate fluorescence-
conjugated antibody were layered to render a color composite image. 
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Observation of “specks” was counted and categorized by cell type (cardiomyocyte, 
non-cardiomyocyte residents, and leukocytes) per field of view (40x). 
 
STATISTICAL ANALYSIS 
 
All data are presented as median and interquartile range; non-parametric tests 
were used because of a potential deviation from a Gaussian distribution. The 
SPSS statistical package 19.0 was used. The Mann-Whitney test was used to 
compare continuous variables between 2 different groups (i.e. cases vs controls), 
the Wilcoxon test was used to compare paired variables within one given group 
(i.e. necrotic region vs remote region of the heart), the Spearman rank test was 
used to define correlation between two variables (i.e. inflammasome specks and 
left ventricular ejection fraction). For each measurement, the effect we were 
interested in detecting was 2SDs from control. Therefore, a sample size of 6 in 
each group had a 80% power to detect an effect size of δ=|µ1-µ2|/σ=2 using an 
estimate from a t-test (2-sided, α=0.05). Multiple comparisons reduces the 
accuracy; as such we maintained a target P<0.05 for this phase with the 
understanding that validation will be required.  
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RESULTS 
 
In this preliminary phase we studied 12 patients with biopsy-documented acute 
myocarditis deriving, 11 cases in which the diagnosis of fatal acute myocarditis 
was made post-mortem, and 5 cases of patients affected by chronic heart disease 
but not of acute cardiac issues selected at autopsy, also in Trieste.  
 
Formation of the inflammasome was detected using immunofluorescence for ASC, 
the scaffold protein that appears as an aggregate, speck(s), during inflammasome 
formation (Figure 4-7). Confirmation was made by colocalization of ASC and 
effector caspase-1, definitive of the inflammasome (Figure 8-10). 
 
The inflammasome was detected in the heart in 10 of 12 cases (83.3%) of biopsy-
proven myocarditis as well as in 8 of 11 cases (72.7%) of post-mortem diagnosis. 
Five cases of non-myocarditis samples showed no presence of the inflammasome. 
In all but 3 cases of post-mortem diagnosis and 2 cases of biopsy-proven 
myocarditis, few inflammasome specks (median 2, range 1-5) per high power field 
(HPF, x40) were seen, and mostly in cardiomyocytes, endothelial cells, or 
fibroblasts. Two cases of fatal myocarditis showed intense staining for the 
inflammasome (30-40 per HPF), mostly in the leukocytes (Figure 11). 
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Figure 4. ASC-cardiac actin co-staining in immunofluorescence. ASC (red) 
conjugated with Alexa Fluor 594, cardiac actin (green) with Alexa Fluor 488, and 
nuclear staining (blue) with DAPI. White arrows point to ASC-positive infiltrating 
cells (e.g. leukocytes). Black arrow points to ASC-positive cardiomyocyte. Bottom 
panel illustrates staining of a control sample with no acute cardiac events.
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Figure 5. ASC-cardiac actin co-staining in cardiomyocytes. Panels shows a 
cardiomyocyte positive for ASC (red) and cardiac actin staining (green), with 
nuclear staining by DAPI (blue).  
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Figure 6. ASC-caveolin co-staining in endothelial cells. Panels show 
endothelial cells positive for ASC (red) and caveolin (green), with nuclear staining 
by DAPI (blue).  
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Figure 7. ASC-S100A4 co-staining in fibroblasts. Panels shows fibroblasts 
positive for ASC (red) and S100A4 (green), with nuclear staining by DAPI (blue).  
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We used co-localization of ASC and caspase-1 to determine the presence of 
aggregates. The specific antibody used for caspase-1, however, recognized both 
the pro-form and cleaved form of caspase-1; hence observation of pro-caspase-1 
was seen also to be constitutive in endothelial cells and leukocytes, independent 
of ASC expression.  
 
Figure 8. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of 
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).  
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Figure 9. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of 
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).  
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Figure 10. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of 
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).  
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Figure 11. Quantitative assessment of total number of ASC+ cells per field of 
image (40x magnification). Averages were taken across 5 images collected from 
each sample and plotted. ASC+ cell count per field (40x magnification) expressed 
as median and inter-quartile range per cell category divided by biopsy and autopsy 
samples, and control samples. 
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DISCUSSION 
 
Acute myocarditis remains a poorly understood pathology, with minimal elucidation 
of the mechanism of action and subsequent deficiency of specific therapies 
leading to a critical outcome. Herein we present a potential new therapeutic target 
in the form of the macromolecular complex inflammasome. 
 
Myocarditis can be infectious in origin or non-infectious. Viral infection and 
subsequent activation of the inflammasome has been studied in previous years.50  
Antiviral immunity has been linked to three distinct inflammasomes: the NLRP3 
inflammasome, RIG-1 inflammasome, and AIM2 inflammasome. These variants all 
involved the adaptor protein apoptosis-associated speck-like protein containing a 
CARD, or ASC, as a link between the sensor and pro-form of caspase-1 that 
ultimately leads to cleavage of pro-inflammatory cytokines IL-1β and IL-18. The 
active forms of these cytokines are coupled to observation of infection, 
inflammation, and autoimmune processes.50 It followed that the likelihood of 
inflammasome formation in acute myocarditis with viral origin was high, a 
phenomenon previously left unstudied. 
 
Samples collected biopsy or autopsy of patients confirmed to have myocarditis 
were delivered from the Cardiomyopathy Registry in Trieste. Tissues were 
embedded in paraffin for preservation. Due to the restrictive nature of sample 
arrangement, most appropriate approach was to utilize immunofluorescence 
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staining. Previous studies have demonstrated this approach to be a viable and 
reliable method of assessment.25 
 
Upon staining, the presence of the scaffold protein ASC was seen in varying 
degrees of both intensity and distribution (Figure 4) in cardiomyocyte, fibroblast, 
and endothelial cells (Figure 5-7) as well as in non-resident infiltrating cells (i.e. 
leukocytes). As an instrumental component of the inflammasome complex, ASC+ 
staining suggested the presence of the inflammasome in the cases of myocarditis 
and not in controls.  
 
ASC+ staining in different cell types demonstrated the presence of the 
inflammasome in a wide array of cells. Using caspase-1 staining we confirmed the 
presence of another essential component of the inflammasome necessary for pro-
inflammatory cytokine cleavage.  
 
To confirm the incidence of the inflammasome, co-staining for ASC and caspase-1 
was conducted for observation of the aggregates in relation to each other – co-
localization indicated formation of the aggregates (Figure 8-10).  
 
For comparison that the observations seen were unique to those with myocarditis, 
samples from patients with no acute cardiac issues were stained for ASC. 
Negative staining in these control subjects indicated that ASC (and the 
inflammasome) are not expressed in the heart, in absence of injury (Figure 11). 
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What remains is observation of the progression of myocarditis and end-stage 
result in linkage with inflammasome presence and activity. 
 
The pathophysiologic role of the inflammasome in acute myocarditis is however 
unclear. Further studies are needed to determine whether the intensity of the 
inflammasome shows correlation to severity of illness at presentation and/or with 
progression to the cardiomyopathy. If the intensity of the inflammasome should 
correlate only with the severity of illness initially but remain inconclusive for 
prediction or is not determinant of clinical progression, inflammasome-targeted 
strategies could be directed selectively towards patients with hemodynamically 
unstable acute myocarditis with a high risk of death acutely but potentially 
favorable recovery with survival (fulminant myocarditis). If the inflammasome 
intensity should not correlate with the severity of the disease or should relate to 
even a milder form of the disease, this could suggest that the inflammasome is a 
protective phenomenon (i.e. virus clearance).24,34 In this event, it suggests the use 
of inflammasome-related therapies (i.e. IL-1β/IL-18) to favor healing. If further 
findings suggest the inflammasome in myocarditis to follow the current paradigm – 
that is the inflammasome as an adverse remodeling agent in the heart – it follows 
that classifying the inflammasome (i.e. particular sensor: NLRP3 vs RIG-1 vs 
AIM2) will be greatly beneficial in adding another target of therapy in addition to 
currently existing modes of treatment.35-37  
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Still it stands that inhibition of the inflammasome may present itself as a potentially 
“double-edged sword.” If inhibition of inflammasome should lead to a weakened 
myocardium following injury, it stands that inflammasome disruption will not be an 
effective method of treatment, and perhaps inhibition of the products of the 
inflammasome, i.e. Interleukin-1β may be preferable.51 In experimental acute 
myocardial infarction, selective blockade of IL-1β protects the heart from apoptosis 
and ameliorates remodeling without intervening in formation of the active 
inflammasome, inhibiting tissue inflammatory response, or disturbing infarct 
healing following AMI.51  Its relevance here is the suggestion that IL-1β blockade 
does not impair tissue response in such conditions as microbial infections.  
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CONCLUSIONS 
 
This study shows for the first time the presence of the inflammasome in the heart 
of patients with myocarditis. This study identifies a potential new pathophysiologic 
mechanism in acute myocarditis opening the way to improved understanding and 
potential improved prognostic stratification and treatment of the disease.   
 
The inflammasome was seen in the heart in 78% of samples with an intensity 
ranging from mild to intense. The pathophysiologic role of the inflammasome 
formation in the heart during acute myocarditis is however unknown. The next step 
will be to accurately quantify the intensity of the formation of the inflammasome 
and analyze for the presence of statistical correlations with the clinical 
characteristics of the patients or the outcomes. 
 
As of 2013, acute myocarditis remains a poorly understood disease with 
unacceptably high morbidity and mortality rates. Identifying an effective and safe 
anti-inflammatory therapy for acute myocarditis represents, therefore, an urgent 
unmet medical need. Therapies directed at IL-1β and IL-18 (products of the 
inflammasome) are already being tested in clinical trials for non-cardiac as well as 
cardiac diseases (other than myocarditis), and novel specific inflammasome 
inhibitors (small molecules) are being developed.  
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We can foresee 3 main possible outcomes: 1) the intensity of the inflammasome 
correlates with the severity of illness at presentation and with progression to the 
cardiomyopathy – this would support studying inflammasome-targeted treatment; 
2) the intensity of the inflammasome correlates with the severity of illness initially 
but does not predict clinical progression – this would support studying 
inflammasome-targeted strategies in selected patients with hemodynamically 
unstable acute myocarditis who have a high risk of death acutely yet if they survive 
have a more favorable recovery; 3) the inflammasome does not correlate with the 
severity of the disease or even associates with a milder form of the disease – this 
would suggest a protective role of the inflammasome (i.e. virus clearance)24,34 and 
suggest the use of inflammasome-related therapies (i.e. IL-1β/IL-18) to favor 
healing. 
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